Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - caspofunginum - liofilizat pentru solutie perfuzabila - 50 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - caspofunginum - liofilizat pentru solutie perfuzabila - 70 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - ganirelixum - solutie injectabila in seringa preumpluta - 0,25 mg/0,5 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp & dohme idea gmbh - vaccin pneumococic - soluţie injectabilă - 25 mcg/0,5 ml (1 doză)

Uniunea Europeană - română - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin, metformin clorhidrat de - diabetul zaharat, tip 2 - medicamente utilizate în diabet - pentru pacienții cu tip 2 de diabet zaharat:efficib este indicat ca adjuvant la dietă și exercițiu fizic pentru îmbunătățirea controlului glicemic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin în monoterapie sau la cei care au fost deja tratați cu asocierea dintre sitagliptin și metformin. efficib este indicat, în asociere cu o sulfoniluree (i. terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. efficib este indicat ca terapie triplă cu un agonist ppar (i. o tiazolidindionă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și un agonist ppar. efficib este, de asemenea, indicat ca adjuvant la insulină (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic pentru îmbunătățirea controlului glicemic, la pacienți atunci când doză stabilă de insulină și metformin în monoterapie nu realizează un control glicemic adecvat.

Uniunea Europeană - română - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimicotice pentru uz sistemic - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 și 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 și 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractară este definită ca progresie a infecției sau eșecul de a îmbunătăți dupa o perioada de minim 7 zile înainte de eficient la doze terapeutice tratamentul antifungic. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 și 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 și 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 și 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractară este definită ca progresie a infecției sau eșecul de a îmbunătăți dupa o perioada de minim 7 zile înainte de eficient la doze terapeutice tratamentul antifungic. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 și 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 și 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractară este definită ca progresie a infecției sau eșecul de a îmbunătăți dupa o perioada de minim 7 zile înainte de eficient la doze terapeutice tratamentul antifungic. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- aspergiloză invazivă la pacienții cu boală rezistentă la amfotericina b sau itraconazol sau la pacienți care nu tolerează aceste medicamente;- fuzarioză la pacienții cu boală rezistentă la amfotericina b sau itraconazol sau la pacienți care nu tolerează amfotericina b;- cromoblastomicoză și micetom la pacienții cu boală rezistentă la itraconazol sau la pacienți care prezintă intoleranță la itraconazol;- coccidioidomicoză la pacienții cu boală rezistentă la amfotericina b, itraconazol sau fluconazol sau la pacienții care au intoleranță la aceste medicamente;- candidoza oro-faringiană: ca terapie de prima linie la pacienții care au boli grave sau sunt imunocompromiși, în care, ca răspuns la terapia topică este de așteptat să fie săraci. refractară este definită ca progresie a infecției sau eșecul de a îmbunătăți dupa o perioada de minim 7 zile înainte de eficient la doze terapeutice tratamentul antifungic. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - corifollitropinum alfa - solutie injectabila in seringa preumpluta - 100 mcg/0,5 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

merck sharp&dohme limited - corifollitropinum alfa - solutie injectabila in seringa preumpluta - 150 mcg/0,5 ml

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

merck sharp & dohme bv - olanda - etoricoxibum - compr. film. - 120mg - antiinflamatoare si antireumatice nesteroidiene coxibi

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

merck sharp & dohme bv - olanda - etoricoxibum - compr. film. - 90mg - antiinflamatoare si antireumatice nesteroidiene coxibi